EMBRYONIC DEVELOPMENT & STEM CELL COMPENDIUM
Content
All Cell Therapies > Cell Therapy Card
Sign in for full access

Embryonic stem cell-derived cardiomyocyte transplantation for myocardial infarction

This study aimed to evaluate the ability of human embryonic stem cells (hESCs) and their cardiomyocyte derivatives (hESC-CMs) to engraft and improve myocardial performance in the rat chronic infarction model. Undifferentiated hESCs or hESC-CMs, were transplanted into rat infarcted hearts, 7-10 days after coronary ligation. Only the hESC-CMs formed stable cardiomyocyte grafts, and improved the typical infarct remodeling process of left ventricle (LV) expansion.
See additional Cell Therapies for: Heart
Embryonic stem cell-derived cardiomyocyte transplantation for myocardial infarction